News

Back

Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress

June 24, 2013

Researchers reported on recent studies demonstrating Bendavia’s ability to improve cardiac function

Boston, MA — June 24, 2013—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers at the European Society of Cardiology (ESC) Heart Failure Congress. Several researchers from Europe and the United States, including Drs. Hani Sabbah and Hazel Szeto, reported on seven recent studies demonstrating Bendavia’s ability to improve cardiac function, preserve viable myocardium and increase survival in systolic and diastolic heart failure models. Stealth is a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs including heart failure and chronic kidney disease. Bendavia is a novel compound that targets mitochondria, restoring bioenergetics in the failing heart. ESC represents more than 80,000 cardiology professionals and provides an array of scientific and educational services and activities. The 2013 Heart Failure Congress was held in Lisbon, Portugal, and is the world’s largest international heart failure congress.

The researchers’ findings presented at the Congress highlighted Bendavia’s ability to restore cellular energetics across the continuum of cardiovascular diseases and improve cardiac and left ventricular performance in chronic heart failure. Dr. Sabbah noted, “Bendavia represents a novel approach to therapy for patients with heart failure by improving mitochondrial energetics in the energy-starved heart. Bendavia has been shown to improve left ventricular function in heart failure models by increasing the availability of adenosine triphosphate or ATP. Given Bendavia’s unique mechanism of action, it has the potential to be complementary to the current standard of care therapies for both systolic and diastolic heart failure.”

Standard models for both acute and chronic cardiovascular diseases have supported Bendavia’s improvement of cardiac performance and survival, and confirm the significance of its novel mechanism of action, which preserves mitochondrial function in disease. Contrary to prior therapeutic strategies in cardiology that focused on uni-targeted pathways, Bendavia and its mitochondria-targeted actions address the more complicated, multifactorial nature of cardiovascular diseases. Specifically, Bendavia maintains electron transport efficiency, mitochondrial respiration and ATP levels, while preventing mitochondrial swelling and depolarization. Bendavia also holds promise as a treatment for acute and chronic kidney diseases and aged-related skeletal muscle dysfunction, both of which are common in heart failure patients and particularly those with diastolic dysfunction, often-termed heart failure with preserved ejection fraction.

Stealth’s CEO, Travis Wilson, remarked, “Stealth is excited about the multiplicity of encouraging findings by researchers at the Congress and Bendavia’s potential for treating the growing prevalence of cardiovascular disease worldwide. We are also pleased that the Congress chose to highlight the innovative research of our European and U.S. collaborators. We believe this recognition confirms a paradigm shift to mitochondria as a novel target for heart failure and Bendavia’s potential to significantly advance the treatment of cardiorenal disease.”

Currently, Stealth is enrolling a multinational Phase II cardiac clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries including the extent of “no-reflow” for patients experiencing acute ST segment elevation myocardial infarction (STEMI). Stealth’s Phase II cardiac study is termed EMBRACE–STEMI™ for the Evaluation of the Myocardial effects of Bendavia for reducing Reperfusion injury in patients with Acute Coronary Events. Stealth is also currently enrolling patients in a Phase II acute kidney injury clinical study to assess the effectiveness of Bendavia on improving chronic renal function affected by severe drug-resistant hypertension.

About Stealth Peptides

Stealth is a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs. Stealth has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500–700 Daltons each) that target mitochondria. Published, peer-reviewed data for these compounds suggest significant in vitro and in vivo efficacy for metabolic, ophthalmologic, neurologic and cardio-renal related disorders. The intellectual property portfolio around these compounds is exceptionally robust with compositions, including Bendavia, protectable by patent until 2031.

More information regarding Stealth and Bendavia is available at our website.

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com